Novel intravesical drug delivery systems explored in bladder cancer
"TAR-200 is a sort of a pretzel device. It's a novel drug delivery mechanism that's placed inside the bladder for sustained release of gemcitabine," explains Siamak Daneshmand, MD.
Study signals benefit with maintenance darolutamide in mCRPC
Patients in the trial received switch maintenance with darolutamide following prior taxane chemotherapy and at least 1 androgen-receptor pathway inhibitor.
Lenvatinib/pembrolizumab survival benefit in kidney cancer sustained with longer follow-up
The updated results were shared at the 2022 International Kidney Cancer Symposium.
Study explores novel combo of pidnarulex and talazoparib in mCRPC
Researchers hope to find synergistic effects with the combination of the ribosomal RNA synthesis inhibitor pidnarulex and the PARP inhibitor talazoparib.
Novel agent may help overcome PD-1 inhibitor resistance in mCRPC
The costimulatory bispecific antibody REGN5678 may alleviate resistance to immune checkpoint inhibition historically observed in prostate tumors.
Expert reviews long-term maintenance avelumab results in urothelial cancer
“This is a new standard of care when managing metastatic bladder cancer patients,” says Joaquim Bellmunt, MD, PhD.
Long-term darolutamide data show sustained efficacy in nmCRPC
The benefit with darolutamide was observed, regardless of whether or not patients had prior local therapy.
Study shows feasibility of mRCC treatment selection based on tumor gene expression
The study specifically examined this precision medicine pathway in the context of frontline treatment selection between nivolumab with or without ipilimumab and a VEGFR tyrosine kinase inhibitor.
Efficacy markers identified for nivolumab/ipilimumab in renal cell carcinoma
An analysis of the phase 2 TITAN-RCC trial found multiple immune cell factors associated with high rates of response to nivolumab/ipilimumab in advanced renal cell carcinoma.
Darolutamide maintenance shows promise in pretreated mCRPC
Patients had received at least 1 novel hormonal agent and had non-progressive disease after subsequent treatment with taxane-based therapy.
Dr. Powles discusses the role of enfortumab vedotin in bladder cancer
Thomas Powles, MBBS, MRCP, MD, discusses where enfortumab vedotin fits in the bladder cancer treatment paradigm.
Antibody-drug conjugate ARX517 joins rapidly expanding PSMA pipeline
ARX517 is being explored in patients with prostate cancer and other PSMA-expressing solid tumors.
Risk-group analysis offers clues to optimizing frontline I/O combos in metastatic kidney cancer
Results from a pooled analysis of frontline treatment in metastatic renal cell carcinoma provided early evidence of a differential overall survival benefit between patients with favorable-risk disease compared to patients with intermediate/poor-risk disease.
2 Clarke Drive Cranbury, NJ 08512